Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

第4相 完了 NCT00200356

概要

This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.

the Rate of Patients With a Modified Rankin Scale Score of 0-1

3 months · participants

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Closed-loop Deep Brain Stimulation to Treat Refractory Neuropathic Pain — Prasad Shirvalkar, MD, PhD
• Women's Health Initiative Strong and Healthy Study — Fred Hutchinson Cancer Center
• Zambia Stroke Unit Study — Johns Hopkins University
• Tracking Post-stroke Walking Improvements From the Clinic Into the Home — Western University of Health Sciences
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
• Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke — Shionogi

すべての治験